Oncology Drugs - Poland

Poland

In Poland, the Oncology Drugs market is anticipated to witness a significant growth in revenue, with projections indicating that it will reach US$0.60bn in 2024.
Moreover, it is expected to maintain a steady annual growth rate (CAGR 2024-2029) of 6.71%.
Consequently, the market volume is estimated to increase to US$0.83bn by 2029.
When compared globally, it is worth noting that United States will generate the highest revenue in the Oncology Drugs market, with an impressive figure of US$103,900.00m in 2024.
Despite facing challenges in access to innovative therapies, Poland has been making significant progress in the development and adoption of targeted oncology drugs.

Key regions: France, Europe, United Kingdom, Brazil, India

Market

Region

Region comparison

Currency

Analyst Opinion

Poland has seen a significant increase in the demand for oncology drugs in recent years.

Customer preferences: The increase in demand for oncology drugs in Poland can be attributed to the aging population, with a larger number of individuals being diagnosed with cancer. Additionally, there is a growing awareness of the benefits of early diagnosis and treatment among the general population, leading to more people seeking medical care.

Trends in the market: One of the major trends in the oncology drugs market in Poland is the increasing use of targeted therapies. These drugs are designed to target specific cancer cells, reducing the risk of damage to healthy cells and improving the effectiveness of treatment. Another trend is the growing popularity of immunotherapy, which uses the body's own immune system to fight cancer cells.

Local special circumstances: Poland has a relatively high incidence of certain types of cancer, such as lung cancer and colorectal cancer. This has led to a higher demand for drugs used in the treatment of these diseases. Additionally, the country has a well-developed healthcare system, with a large number of hospitals and medical centers offering oncology services.

Underlying macroeconomic factors: The increasing demand for oncology drugs in Poland is driven by a combination of demographic and economic factors. The aging population is a major driver, as older individuals are more likely to develop cancer. Additionally, the country's strong economic growth has led to increased healthcare spending, which has allowed for the development and availability of more advanced treatments. The government's focus on improving access to healthcare services has also contributed to the growth of the oncology drugs market in Poland.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.